Bio Path Holdings Stock Total Debt
| BPTH Stock | USD 2.61 0.05 1.88% |
Bio Path Holdings fundamentals help investors to digest information that contributes to Bio Path's financial success or failures. It also enables traders to predict the movement of Bio Stock. The fundamental analysis module provides a way to measure Bio Path's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bio Path stock.
The current Total Debt To Capitalization is estimated to decrease to 0.19. Bio | Total Debt |
Bio Path Holdings Company Total Debt Analysis
Bio Path's Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Bio Path Total Debt | 113 K |
Most of Bio Path's fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bio Path Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Bio Total Debt Driver Correlations
Understanding the fundamental principles of building solid financial models for Bio Path is extremely important. It helps to project a fair market value of Bio Stock properly, considering its historical fundamentals such as Total Debt. Since Bio Path's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Bio Path's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Bio Path's interrelated accounts and indicators.
Click cells to compare fundamentals
Bio Total Debt Historical Pattern
Today, most investors in Bio Path Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Bio Path's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total debt growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Bio Path total debt as a starting point in their analysis.
Bio Path Total Debt |
| Timeline |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Bio Short Long Term Debt Total
Short Long Term Debt Total |
|
Based on the latest financial disclosure, Bio Path Holdings has a Total Debt of 113 K. This is 100.0% lower than that of the Biotechnology sector and 99.97% lower than that of the Health Care industry. The total debt for all United States stocks is 100.0% higher than that of the company.
Bio Path Holdings is the top company in total debt category among related companies. Total debt of Health Care industry is currently estimated at about 116,523. Bio Path totals roughly 113,000 in total debt claiming about 97% of equities under Health Care industry.Bio Path Institutional Holders
Institutional Holdings refers to the ownership stake in Bio Path that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Bio Path's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Bio Path's value.| Shares | Bank Of America Corp | 2023-12-31 | 152 | Hanson Mcclain Inc | 2023-12-31 | 150 | Wells Fargo & Co | 2023-12-31 | 95.0 | Global Retirement Partners, Llc. | 2023-12-31 | 69.0 | Royal Bank Of Canada | 2023-12-31 | 20.0 | Advisor Group Holdings, Inc. | 2023-12-31 | 10.0 | Warberg Asset Management Llc | 2023-12-31 | 0.0 | Millennium Management Llc | 2023-12-31 | 0.0 | Virtu Financial Llc | 2023-09-30 | 0.0 | Vanguard Group Inc | 2023-12-31 | 270 K | Geode Capital Management, Llc | 2023-12-31 | 110.4 K |
Bio Fundamentals
| Return On Equity | -2.2 | ||||
| Return On Asset | -1.03 | ||||
| Current Valuation | 832.65 K | ||||
| Shares Outstanding | 1.57 M | ||||
| Shares Owned By Insiders | 0.10 % | ||||
| Shares Owned By Institutions | 1.79 % | ||||
| Number Of Shares Shorted | 27.36 K | ||||
| Price To Earning | (6.21) X | ||||
| Price To Book | 5.21 X | ||||
| EBITDA | (15.66 M) | ||||
| Net Income | (16.08 M) | ||||
| Cash And Equivalents | 17.02 M | ||||
| Cash Per Share | 2.38 X | ||||
| Total Debt | 113 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 15.57 X | ||||
| Book Value Per Share | 0.71 X | ||||
| Cash Flow From Operations | (11.54 M) | ||||
| Short Ratio | 0.80 X | ||||
| Earnings Per Share | (33.63) X | ||||
| Target Price | 40.0 | ||||
| Number Of Employees | 10 | ||||
| Beta | 0.38 | ||||
| Market Capitalization | 4.09 M | ||||
| Total Asset | 3.22 M | ||||
| Retained Earnings | (107.61 M) | ||||
| Working Capital | 1.14 M | ||||
| Current Asset | 9.59 M | ||||
| Current Liabilities | 937 K | ||||
| Net Asset | 3.22 M |
About Bio Path Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bio Path Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bio Path using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bio Path Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Bio Path
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bio Path position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bio Path will appreciate offsetting losses from the drop in the long position's value.Moving against Bio Stock
| 0.76 | SNDL | SNDL Inc Earnings Call This Week | PairCorr |
| 0.69 | CGC | Canopy Growth Corp Financial Report 27th of June 2024 | PairCorr |
| 0.68 | IMCC | Im Cannabis Corp Earnings Call This Week | PairCorr |
| 0.65 | PAHC | Phibro Animal Health Earnings Call This Week | PairCorr |
| 0.64 | QLI | Qilian International | PairCorr |
The ability to find closely correlated positions to Bio Path could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bio Path when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bio Path - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bio Path Holdings to buy it.
The correlation of Bio Path is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bio Path moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bio Path Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bio Path can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Bio Path Piotroski F Score and Bio Path Altman Z Score analysis. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Complementary Tools for Bio Stock analysis
When running Bio Path's price analysis, check to measure Bio Path's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bio Path is operating at the current time. Most of Bio Path's value examination focuses on studying past and present price action to predict the probability of Bio Path's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bio Path's price. Additionally, you may evaluate how the addition of Bio Path to your portfolios can decrease your overall portfolio volatility.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Commodity Directory Find actively traded commodities issued by global exchanges |
Is Bio Path's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Path. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Path listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (33.63) | Return On Assets (1.03) | Return On Equity (2.20) |
The market value of Bio Path Holdings is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Path's value that differs from its market value or its book value, called intrinsic value, which is Bio Path's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Path's market value can be influenced by many factors that don't directly affect Bio Path's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Path's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Path is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Path's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.